Feature

FDA: Puerto Rico’s medical supply shortage issues continue


 

Food and Drug Administration officials are warning of continued medical supply shortages in Puerto Rico in the aftermath of Hurricane Maria.

“In addition to our ongoing concerns related to IV saline products, we also are particularly focused on the shortage of amino acids for injection,” FDA Commissioner Scott Gottlieb, MD, said in a statement.

FDA icon Wikimedia Commons/FitzColinGerald/Creative Commons License
To address the shortage of intravenous saline, the FDA has been working with the supplier Baxter to help restore production in its local facilities and has also approved IV saline products from Fresenius Kabi and Laboratorios Grifols, which have stepped up production to help meet the need. The IV saline shortage is expected to improve by the end of 2017, Dr. Gottlieb said.

The shortage of amino acids for injection predates Hurricane Maria, but the hurricane’s impact worsened the situation by disrupting Baxter’s ability to manufacture amino acids in Puerto Rico. The FDA has worked with Baxter to temporarily import pediatric and adult amino acid injections from the United Kingdom and Italy, as well as working with other amino acid manufacturers to increase supplies.

“We continue to work closely with federal and Puerto Rican authorities to address the needs of manufacturers on the island for power and other resources. These efforts have been focused on the needs of patients – to prevent potential shortages of medically important products where possible, and help ensure that any shortages that do occur are mitigated as quickly as possible,” Dr. Gottlieb said.

Read the full statement on the FDA website.

Recommended Reading

MACRA Monday: Documenting current medications
MDedge Hematology and Oncology
Former pharma exec nominated for top HHS post
MDedge Hematology and Oncology
FDA addresses cell-based regenerative medicine in comprehensive new policy
MDedge Hematology and Oncology
MACRA Monday: Elder maltreatment screening
MDedge Hematology and Oncology
CMS to enlist Medicare Part D plans to combat opioid abuse
MDedge Hematology and Oncology
FDA grants orphan drug status to rofecoxib for hemophilic arthropathy
MDedge Hematology and Oncology
Marketplace confusion opens door to questions about skinny plans
MDedge Hematology and Oncology
HealthCare.gov seeing more action this fall
MDedge Hematology and Oncology
Drug prices a key focus of Senate HELP examination of Azar nomination
MDedge Hematology and Oncology
5 big ways the tax bill could affect health policy
MDedge Hematology and Oncology